# US 2010/0166887 A1 · DIBENZO[b,e][1,4]DIAZEPINE MODULATORS OF DOPAMINE RECEPTORS, SEROTONIN RECEPTORS, ADRENERGIC RECEPTORS, ACETYLCHOLINE RECEPTORS, AND/OR HISTAMINE RECEPTORS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166887 A1
- Document ID: US20100166887A1
- Status: Published application
- Kind: A1
- Application number: 12/582,816
- Filed: 2009-10-21
- Published: 2010-07-01
- Earliest claimed: 2008-10-22
- Assignees: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant; Sepehr Sarshar
- Web page: https://patentgrep.com/patent/US20100166887A1

## CPC

- C07D 243/38: [b, e]- or [b, f]-condensed with six-membered rings
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new dibenzo[b,e][1,4]diazepine modulators of dopamine receptors, serotonin receptors, adrenergic receptors, acetylcholine receptors, and/or histamine receptors, pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound of structural Formula I
or a salt thereof, wherein:
R1-R19 are independently selected from the group consisting of hydrogen and deuterium;
at least one of R1-R19 is deuterium; and
if R8-R11 are each deuterium, then at least one of R1-R7 and R12-R19 is deuterium.

### Claim 2 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R19 independently has deuterium enrichment of no less than about 10%.

### Claim 3 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R19 independently has deuterium enrichment of no less than about 50%.

### Claim 4 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R19 independently has deuterium enrichment of no less than about 90%.

### Claim 5 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R19 independently has deuterium enrichment of no less than about 98%.

### Claim 6 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 7 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 8 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%.

### Claim 9 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%.

### Claim 10 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%.

### Claim 11 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%.

### Claim 12 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 13

A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I
or a salt thereof, wherein:
R1-R19 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R19 is deuterium.

### Claim 14

A method of treatment of a dopamine receptor-mediated disorder, a serotonin receptor-mediated disorder, an adrenergic receptor-mediated disorder, an acetylcholine receptor-mediated disorder, or a histamine receptor-mediated disorder comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound of structural Formula I
or a salt thereof, wherein:
R1-R19 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R19 is deuterium.

### Claim 15 (depends on 14)

The method as recited in claim 14 wherein said dopamine receptor-mediated disorder, serotonin receptor-mediated disorder, adrenergic receptor-mediated disorder, acetylcholine receptor-mediated disorder, or histamine receptor-mediated disorder is a psychotic disorder.

### Claim 16 (depends on 15)

The method as recited in claim 15 wherein said psychotic disorder is schizophrenia.

### Claim 17 (depends on 14)

The method as recited in claim 14 further comprising the administration of an additional therapeutic agent.

### Claim 18 (depends on 17)

The method as recited in claim 17 wherein said additional therapeutic agent is selected from the group consisting of lithium and valproate.

### Claim 19 (depends on 17)

The method as recited in claim 17 wherein said additional therapeutic agent is selected from the group consisting of antidepressants, mood stabilizers, and antipsychotics.

### Claim 20 (depends on 19)

The method as recited in claim 19 wherein said antidepressant is selected from the group consisting of citalopram, escitalopram, paroxetine, fluotexine, fluvoxamine, sertraline, isocarboxazid, moclobemide, phenelzine, tranylcypromine, amitriptyline, clomipramine, desipramine, dosulepin, imipramine, nortriptyline, protriptyline, trimipramine, lofepramine, maprotiline, amoxapine, mianserin, mirtazapine, duloxetine, nefazodone, reboxetine, trazodone, venlafaxine, tianeptine, and milnacipran.

### Claim 21 (depends on 19)

The method as recited in claim 19 wherein said antipsychotic is selected from the group consisting of chlorpromazine, levomepromazine, promazine, acepromazine, triflupromazine, cyamemazine, chlorproethazine, dixyrazine, fluphenazine, perphenazine, prochlorperazine, thiopropazate, trifluoperazine, acetophenazine, thioproperazine, butaperazine, perazine, periciazine, thioridazine, mesoridazine, pipotiazine, haloperidol, trifluperidol, melperone, moperone, pipamperone, bromperidol, benperidol, droperidol, fluanisone, oxypertine, molindone, sertindole, ziprasidone, flupentixol, clopenthixol, chlorprothixene, thiothixene, zuclopenthixol, fluspirilene, pimozide, penfluridol, loxapine, clozapine, olanzapine, quetiapine, tetrabenazine, sulpiride, sultopride, tiapride, remoxipride, amisulpride, veralipride, levosulpiride, lithium, prothipendyl, risperidone, clotiapine, mosapramine, zotepine, pripiprazole, and paliperidone.

### Claim 22 (depends on 19)

The method as recited in claim 19 wherein said mood stabilizer is selected from the group consisting of lithium carbonate, lamotrigine, sodium valproate, carbamazepine, triacetyluridine, and topiramate.

### Claim 23 (depends on 14)

The method as recited in claim 14, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 24 (depends on 14)

The method as recited in claim 14, further resulting in at least two effects selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 25 (depends on 14)

The method as recited in claim 14, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 26 (depends on 25)

The method as recited in claim 25, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

### Claim 27 (depends on 14)

The method as recited claim 14, wherein said compound is characterized by decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 28 (depends on 27)

The method as recited in claim 27, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYP 1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4×1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB.

### Claim 29 (depends on 14)

The method as recited in claim 14, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

### Claim 30 (depends on 29)

The method as recited in claim 29, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

### Claim 31

A compound for use as a medicament, said compound having structural Formula I
or a salt thereof, wherein:
R1-R19 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R19 is deuterium.

### Claim 32

A compound for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by the modulation of dopamine receptors, serotonin receptors, adrenergic receptors, acetylcholine receptors, or histamine receptors, said compound having structural Formula I
or a salt thereof, wherein:
R1-R19 are independently selected from the group consisting of hydrogen and deuterium; and
at least one of R1-R19 is deuterium.
